Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$3.06 ▼ -0.07
(-2.24%)
MKT CAP: $251.1M • VOL: 1.05M
52W L $3 52W H $11
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
LXEO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$109.3M | -$105.8M | -$68.5M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$100.0M | -$98.3M | -$66.4M |
| EBITDA (Normalized) | -$108.9M | -$105.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$98.6M | -$81.2M | -$59.5M |
| Capital Expenditures (CapEx) | $397.0K | $481.0K | — |
| Free Cash Flow (FCF) | -$99.0M | -$81.6M | -$59.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $63.0M | $35.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $246.7M | $116.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LXEO.